NQ Minerals 'in a good position' and continuing to ramp up production at Hellyer
Kazia Therapeutics Phase II Paxalisib glioblastoma study shows positive overall survival signal data
Zelira Therapeutics shares surge after clinically validating medicinal cannabis for insomnia
The parties have agreed on minimum annual revenue thresholds that start at US$300,000 for the calendar year 2021 and increase annually thereafter
The oncology-focused biotechnology company has two clinical-stage drug development candidates in the pipeline.
Insomnia is a large unmet medical need. It affects ~30% of the US population and is a major risk factor for patients suffering chronic pain and neurological disorders.